BioNxt starts large-animal pharmacokinetic study of sublingual everolimus film for transplant rejection

• BioNxt launched a comparative large-animal pharmacokinetic study for a sublingual everolimus oral dissolvable film aimed at transplant rejection.
• Results have not been presented; data are expected within about two months after payment and delivery of test samples.
• The readout is intended to support selection of a lead formulation and inform dose planning for later human studies.
• The program targets more consistent drug exposure than conventional oral everolimus, which can vary with digestion and food intake.
• BioNxt is assessing a potential European hybrid regulatory pathway for a product that changes the route of administration versus existing everolimus medicines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNxt Solutions Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609080305ACCESSWRNAPR_____1217946) on September 08, 2026, and is solely responsible for the information contained therein.